Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID‐19‐associated organ failure

Stem Cells Translational Medicine

卷:10

Annelise Bennaceur‐Griscelli¹  Frank Griscelli¹  Jusuf Imeri¹  Thomas Lemonnier¹  Theodoros Latsis¹  Christophe Desterke¹  Ali G. Turhan¹  Paul Marcoux¹ 

[1] INSERM UMR‐S 935 and University Paris Saclay Villejuif France;

关键词: adult human bone marrow;    embryonic stem cells;    induced pluripotent stem cells;    lymphocytes;    mesenchymal stem cells;   

DOI  :  10.1002/sctm.20-0189

来源: DOAJ

【 摘 要 】

Abstract The use of mesenchymal stem cells (MSC) derived from several sources has been suggested as a major anti‐inflammation strategy during the recent outbreak of coronavirus‐19 (COVID‐19). As the virus enters the target cells through the receptor ACE2, it is important to determine if the MSC population transfused to patients could also be a target for the virus entry. We report here that ACE2 is highly expressed in adult bone marrow, adipose tissue, or umbilical cord‐derived MSC. On the other hand, placenta‐derived MSC express low levels of ACE2 but only in early passages of cultures. MSC derived from human embryonic stem cell or human induced pluripotent stem cells express also very low levels of ACE2. The transcriptome analysis of the MSCs with lowest expression of ACE2 in fetal‐like MSCs is found to be associated in particularly with an anti‐inflammatory signature. These results are of major interest for designing future clinical MSC‐based stem cell therapies for severe COVID‐19 infections.

【 授权许可】

Unknown